Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106952 | 0.81 | DGAT1 (0.39) | PDE10AADORA3TSPOADORA1CDK1 | |
| SCHEMBL24955640 | 0.79 | PIK3CA (0.47) | PDE10AADORA1 | |
| SCHEMBL30202390 | 0.79 | PDE10A (0.38) | PDE10AADORA3TSPOADORA1 | |
| SCHEMBL24955686 | 0.79 | PDE10A (0.38) | PDE10AADORA3TSPOADORA1 | |
| SCHEMBL31106986 | 0.79 | PDE10A (0.43) | PDE10A | |
| SCHEMBL30203054 | 0.77 | CNR2 (0.38) | PDE10AADORA1 | |
| SCHEMBL30202168 | 0.75 | MTOR (0.49) | PDE10A | |
| SCHEMBL30202248 | 0.75 | MTOR (0.49) | PDE10A | |
| SCHEMBL31106946 | 0.72 | DGAT1 (0.35) | PDE10AADORA3TSPOADORA1 | |
| SCHEMBL14843067 | 0.71 | PDE10A (0.46) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | PDE10A 733/4885ADORA3 1646/4885TSPO 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.